Background Human mesenchymal stem cells (hMSCs) only have a limited diff erentiation
INTRODUCTION
Intramyocardial mononuclear bone marrow cell (BMC) transplantation is a promising new treatment modality in patients after myocardial infarction (MI) [1] or with therapy-refractory myocardial ischemia [2] as BMC injections in ischemic myocardium improved myocardial perfusion as well as left ventricular ejection fraction, possibly mediated by neoangiogenesis [2, 3] . The mononuclear BMC fraction contains mesenchymal stem cells (MSCs), which are easily expandable and are able to diff erentiate into multiple cell lineages [4] . As shown previously, intramyocardial MSC transplantation improves angiogenesis [5] and left ventricular (LV) function in diff erent animal models [6, 7, 8] . Furthermore, MSCs can diff erentiate into cardiomyocytes in vitro under appropriate conditions [9] . However, it is unclear whether in vivo myogenic diff erentiation of bone marrow (BM) stem cells, including MSCs [10] , actually occurs; at best the diff erentiation rate seems to be rather low [11] . Theoretically it is preferable that cell therapy results in the generation of new cardiomyocytes to replace cells lost after an acute ischemic event. Novel approaches to identify signals guiding myogenic diff erentiation into the cardiac lineage have therefore been proposed [12] . Ex-vivo pretreatment of MSCs with the DNA demethylating agent 5'-azacytidine [3, 9] or growth factors including bFGF, IGF-1 and BMP-2 [13] forming Growth Factor-ß1 (TGF-ß1) induced the expression of several cardiomyocyte-specifi c proteins resulting in functional cardiac regeneration in a mouse model of acute MI (AMI) [14] .
So far, no eff orts have been made to enhance diff erentiation of MSCs into the cardiomyogenic cell lineage through genetic modifi cation.
Myocardin is a pivotal cardiomyogenic transcription factor, that transactivates the ubiquitous transcription factor serum response factor (SRF) [15] . Myocardin regulates the expression of many growth-related and muscle-restricted genes [16] . Overexpression of the longest splice variant of the human myocardin gene in human MSCs (hMSCs) [17] and human myocardial scar fi broblasts [18] induced the expression of cardiac and smooth muscle cell (SMC) genes in vitro, without expression of skeletal muscle genes [17] . Therefore it was hypothesized that forced myocardin expression in hMSCs may enhance their propensity to diff erentiate into cardiomyocytes in vivo, thereby increasing the potential therapeutic eff ect of mesenchymal stem cell therapy in patients with ischemic heart disease (IHD). In this study the eff ects of forced myocardin expression in hMSC from IHD patients on the in vivo engraftment rate, diff erentiation and preservation of LV function were evaluated in an immune-compromised mouse model of AMI.
C H A P T E R 6 : F O R C E D M Y O C A R D I N E X P R E S S I O N E N H A N C E S T H E T H E R A P E U T I C E F F E C T O F H U M A N M E S E N C H Y M A L S T E M C E L L S A F T E R T R A N S P L A N T A T I O N I N I S C H E M I C M O U S E H E A R T S

R E G E N E R A T I V E M E D I C I N E I N C A R D I O V A S C U L A R D I S E A S E : F R O M T I S S U E E N G I N E E R I N G T O T I S S U E R E G E N E R A T I O N
METHODS
Animals
All experiments were approved by the institutional committee on animal welfare. To avoid rejection of injected human cells, experiments were performed in 8-10 weeks old male NOD/Scid mice (Charles River Laboratories, Maastricht, the Netherlands 
Purification and Expansion of hMSC
Human cellular material was obtained after written informed consent and experiments were approved by the institutional medical ethics committee. BM samples were obtained from 4 adult IHD patients who were enrolled in ongoing clinical stem cell trials [2] . hMSC were purifi ed as described previously [17] , expanded by serial passage, and used from passages 3 to 8 in culture conditions. The hMSC surface antigen profi le was characterized as previously described [17] . hMSCs abundantly expressed hyaluronate receptor (CD44), major T-cell antigen (Thy-1; CD90), endoglin (CD105), vascular cell adhesion molecule-1 (CD106), and human leukocyte class I (HLA-ABC) antigens. These cells also expressed low levels of transferrin receptor (CD71), P-selectin (CD62P), ß3 integrin (CD61), neural cell adhesion molecule (CD56), and membrane cofactor protein of the complement system (CD46) at their surface. hMSCs diff erentiated into adipocytes and osteoblasts after proper stimulation confi rming their multipotent nature (data not shown).
Adenov iruses and Gene Transfer
The generation of the fi ber-modifi ed human adenovirus serotype 5 vectors encoding human myocardin (hAd5/F50.CMV.myocL), the enhanced green fl uorescent protein (eGFP) gene (hAd5/ F50.CMV.eGFP) and the control vector (hAd5/F50.empty) were described elsewhere [17] . Before transduction, hMSC were seeded at a density of 2E4 hMSCs per cm 2 in 10 cm 2 dishes, and cultured overnight. Next, the culture medium (DMEM+10 % FBS) was replaced by 1 ml fresh culture After 10-20 minutes after AMI, animals were grouped to receive injections of 2x10 5 hMSCs transduced with eGFP and myocardin in 20μl culture medium (MI+hMSC myoc group, n = 10), hMSCs transfected with eGFP and empty vector (MI+hMSC group, n = 10) or medium only (MI+Medium group, n = 12). Sham operated animals were used to determine baseline characteristics (Sham group, n = 12). The intramyocardial injections were performed at 5 sites within infarcted area and the borderzone using a 20μl Hamilton syringe with a 33G needle. The chest was closed in layers and animals were allowed to recover.
Cardiac Magnetic Resonance Imaging
Left ventricular anatomy and function were serially assessed 2 and 14 days after surgery by magnetic resonance imaging (MRI). The MRI setup consisted of a vertical 9.4T (400 MHz), 89 mm bore NMR spectrometer equipped with a shielded gradient set (1T/m) and a 30 mm birdcage resonator (Bruker Biospin, Rheinstetten, Germany). Mice were anaesthetised as described above and maintained at 1-2 % isofl uorane. Biotrig software (Bruker, Rheinstatten, Germany) was used to monitor ECG and respiratory rate. Image reconstruction was performed using Bruker ParaVision 3.02 software.
I N F A R C T S I Z E
To determine the extent of the infarcted area at day 2, contrast enhanced MRI imaging was employed after injection of a 150 μL (0.05 mmol/ml) bolus of gadolinium-DPTA (Gd-DPTA, Dotarem, Guerbet) via the tail vein. A high-resolution ECG-and respiratory-triggered 2D fast gradient echo (FLASH) sequence was used to acquire a set of 18 contiguous 0.5 mm slices in short-axis orientation covering the entire heart. Imaging parameters were: echo time (TE) of 1.9 ms, repetition time (TR) of 90.5 ms, fi eld of view (25.60 mm) 2 , matrix size 256x256 (resulting in a resolution of 100 μm) and a fl ip angle of 60º.
At day 2 and day 14, LV dimensions were assessed. A high-resolution 2D FLASH cine sequence was used to acquire a set of contiguous 1 mm slices in short-axis orientation covering the entire long-axis of the heart. Imaging parameters were: echo time (TE) of 1.9 ms, repetition time (TR) of 7 ms, fi eld of view (25.6 mm) 2 , matrix size 256x256 and a fl ip angle of 15°. 
Left Ventricular Function by Pressure-Volume Loops
Instrumentation A 1.4 F pressure-conductance catheter (SPR-719, Millar Instruments, Houston, TX) was introduced via the right carotid artery, positioned into the LV, and connected to a Sigma-SA signal processor (CD Leycom, Zoetermeer, The Netherlands). Calibration was performed as previously described [19] .The abdomen was opened to enable temporary preload reductions by directly compressing the inferior vena cava. All data were acquired using Conduct-NT software (CD Leycom) at a sample rate of 2000 Hz and analyzed off -line with custommade software.
Pressure-volume relations LV pressure-volume signals were acquired in steady state to quantify general hemodynamic conditions: Heart rate (HR), stroke volume (SV), cardiac output (CO), EDV, ESV, EF, end-diastolic pressure (EDP), and end-systolic pressure (ESP) were determined.
Stroke work (SW) was determined as the area of the pressure-volume loop, and the maximal and minimal rate of LV pressure change, dP/dt MAX and dP/dt MIN , and the isovolumic relaxation time constant Tau were calculated. Load-independent indices of systolic and diastolic LV function were determined from pressure-volume relations obtained during preload reductions. To quantify systolic function, we used the end-systolic pressure-volume relation (ESPVR), the relation between dP/dt MAX and EDV, and the preload recruitable stroke work relation (PRSWR: SW versus EDV). The slopes of these relations, E ES (end-systolic elastance), S-dP, and S-PR, respectively, are sensitive measures of intrinsic systolic LV function. In addition, the positions of the pressure-volume relations were quantifi ed by their intercepts at, respectively ESP = 82 mm SW = 1059 mmHg.μL and dP/dt MAX = 6090 (These levels were selected retrospectively as the overall mean values of ESP, SW and dP/dt MAX for all groups). For diastolic function, the chamber stiff ness E ED was determined from a linear fi t to the end-diastolic pressure-volume points.
Histological Examination
At day 15 mice were sacrifi ced and hearts and lungs removed. The body weight and wet lung weight were measured from all animals and lungs were then freeze-dried. The diff erence between wet and dry lung-weight was used as a measure of pulmonary congestion.
From each group, four hearts were immersion-fi xed in 4 % paraformaldehyde, dehydrated in graded ethanol and xylene and subsequently embedded in paraffi n. Serial sections of 5 μm were cut along the entire long-axis of the LV for immunohistochemical analysis. Sections were deparaffi nated and dehydrated in xylene and graded alcohol. Antigen retrieval was performed by heating in a microwave oven (97 °C) in 0.01 M citric buff er of pH 6.0 for 10 minutes. Sections were incubated overnight at room temperature with the primary antibodies diluted in PBS with 1 % BSA and 0.05 % Tween.
E N G R A F T M E N T R A T E O F T R A N S P L A N T E D h M S C s
hMSC engraftment was detected by immunostaining with a rabbit anti-GFP antibody (A11122, Molecular Probes Inc.) followed by a biotinylated goat anti-rabbit IgG (BA-1000, Vector Labs, Burlingame, CA, USA). For visualisation of the eGFP specifi c anti-body, the signal was amplifi ed with the ABC staining kit (PK-6100, Vector Labs). 3,3'-diamino-benzidine tetrahydrochloride (D5637, Sigma-Aldrich) was used as substrate for horseradish peroxidise. Sections were counterstained with Mayer's hematoxillin.
The number of engrafted hMSCs was determined by counting the GFP positive cells with a 20x magnifi cation in every 10th serial section of the entire long axis of the heart. Only elongated cells with a length >20 μm were counted. The number of GFP-positive cells was multiplied by 10 to estimate the total number of engrafted cells in the heart. The hMSC engraftment rate was calculated by dividing this number by the number of injected hMSCs (2 × 10 5 cells).
A S S E S S M E N T O F C E L L D I F F E R E N T I A T I O N
Double immunostainings were performed with mouse monoclonal antibodies against α-sarcomeric actin (αSA, clone 5C5, A2172, Sigma-Aldrich), Atrial Natriuretic Factor (ANF, CBL66, Chemicon), anti-cardiac-troponin T (cTnT, AB33589, Abcam), troponin I (cTnI; clone 19C7, HyTest) and a polyclonal rabbit anti-myosin light chain 2a (MLC2a, gift from S.W. Kubalek).
Primary Abs were visualized with appropriate secondary biotinylated Abs followed by Qdot 655 streptavidin-conjugated (Q10121MP, Invitrogen) Abs. The eGFP labelled cells were detected by immunostaining with monoclonal rabbit anti-GFP or polyclonal goat anti-GFP (AB6673, Abcam)
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antibodies followed by an appropriate donkey Alexa Fluor 488 antiserum (A21206 and A11055).
Colocalization of eGFP and diff erentiation markers was examined using dedicated Q-dot compatible fi lter sets.
D I F F E R E N T I A T I O N I N V I T R O
To compare the protein expression of in vitro cultured and in vivo injected hMSCs, a small fraction of hMSCs and hMSCs myoc from the same cell batch that was injected in the mice was propagated ex vivo. The cells were maintained in vitro for 15 days and evaluated for cardiomyocyte-specifi c protein expression by immunofl uorescence staining using the same aforementioned antibodies.
A N A L Y S I S O F V A S C U L A R D E N S I T Y
To determine the eff ect of hMSC transplantation on vascular density, vascular endothelial cells were stained with a PECAM-1 antibody (CD31, clone MEC13.3, Pharmingen, San Diego, CA, USA)
followed by a biotinylated goat anti-rat IgG (Pharmingen). Visualisation was enhanced by the CSA system (K1500, DAKO). The percentage of PECAM-1 staining was measured using the Image-Pro Plus software package (Media Cybernetics Inc., Carlsbad, CA, USA). The value was expressed as the ratio of the sum of all areas containing PECAM divided by the total area of the image. The measurements were performed by two independent examiners who were blinded to the treatment assignment.
Statistical Analysis
Numerical values were expressed as means ± SEM. Comparisons of parameters between the Sham, Medium, hMSC and hMSCmyoc groups were made using one-way analysis of variance (ANOVA). If the omnibus tests among groups were signifi cantly diff erent, post-hoc tests between groups using unpaired t-tests were used. A p-value < 0.05 was considered signifi cant. No diff erence in infarct size was found 2 days after MI between the MI+Medium, MI+hMSC and MI+hMSC myoc groups (P = ns).
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RESULTS
LV Infarct Size, Volumes and Function
Two days after coronary artery ligation, infarct size was determined in all mice in the Medium (n = 12), hMSC (n = 10) and hMSC myoc (n = 10) groups by contrast-enhanced MRI with Gd-DPTA ( Fig. 1A and B) . Infarct size did not diff er between the three groups (36 ± 2 % vs. 32 ± 2 vs. 31 %, resp.; Fig. 1C ) indicating that cell injection had no early positive eff ect on the infarct size.
Cardiac volumes and ejection fraction were evaluated 2 and 14 days after myocardial infarction by MRI. Representative examples of systolic and diastolic 3D reconstructions of MRI short axis views for all four experimental groups at day 14 are shown in Figure 2A .
Compared to Sham animals (EDV 48 ± 2 μl; ESV 24 ± 1 μl; LVEF 51 ± 1 %, P < 0.05), 2 days after AMI, all MI groups developed typical changes indicative of LV remodeling as refl ected by an increase in EDV (Medium: 61 ± 2 μl, hMSC: 59 ± 3 μl, hMSC myoc : 57 ± 3 μl), and ESV (Medium, 42 ± 2 μl; hMSC, 40 ± 3 μl; hMSC myoc , 38 ± 3 μl), and a decrease in LVEF (Medium 30 ± 2 %; hMSC 33 ± 3 %; hMSC myoc 34 ± 2 %) ( Fig. 2B-D ). There were no signifi cant diff erences in LV parameters between the 3 MI groups at day 2 post MI.
At day 14 post MI, there was a further decrease of LVEF and a progression of LV remodeling in all MI groups (Fig. 2B-D) . However, LVEF deterioration in the hMSC and the hMSC myoc group (25 ± 3 % vs. 27 ± 3 %) was signifi cantly attenuated as compared to the Medium group (15 ± 1 %, P < 0.05). Interestingly, LV remodeling in the hMSC myoc group was signifi cantly reduced (EDV:
104 ± 7 μl and ESV: 78 ± 8 μl) as compared to the Medium group (133 ± 8 μl and 114 ± 9 μl, resp., both P < 0.05), whereas for hMSC group no diff erence was observed compared to the medium group (115 ± 13 μl and 90 ± 14 μl, resp.; both p = ns). 
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Hemodynamic M easurements
The functional pressure-volume-derived data for all 4 groups are presented in table 1. Summarized schematic pressure-volume loops (based on mean end-systolic and end-diastolic pressures and volumes) and mean end-systolic pressure-volume relations for all four groups are shown in Figure 3 . 
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In both hMSC and hMSC myoc groups an improvement in dP/dt MAX , SW, ESV INT and E ED was observed as compared to the MI+Medium group.
In addition, in the hMSC myoc group but not in the hMSC group ESP, Tau, -dP/dt MIN , E ES , EDV INT and the slope and intercept of the dP/dt MAX -EDV relation were also improved. In comparison to the hMSC vs. the hMSC myoc group, a signifi cant diff erence was observed for Tau and ESV INT , whereas the intercepts of PRSW and the dP/dt MAX -EDV relation displayed a non-signifi cant trend. 
hMSC Engraftment and Differentiation
Fifteen days after cell transplantation, substantial engraftment was observed in both cell transplant groups (Figure 4A and B) . However, quantitative assessment revealed a signifi cant higher engraftment rate in the hMSCs myoc group (5.8 ± 0.5 %) as compared to the hMSC group (4.2 ± 0.3 %, p < 0.05) (Fig. 4C ). Sections were examined to assess diff erentiation of hMSC and hMSC myoc into a cardiomyocyte-like phenotype. None of the injected hMSCs expressed αSA, MLC2a, ANF, cTnT and cTnI (Fig. 5, left panel) . In contrast, over expression of myocardin in hMSCs resulted in expression of sarcomeric α-actin, MLC2a, ANF, and cTnT (Fig. 5, right panel) . The diff erentiation rate of the engrafted cells was approximately 90-100 % for the various diff erentiation markers. The staining pattern for these proteins was however diff use, and we did not observe cross striations in the hMSCs myoc . Furthermore none of the hMSCs myoc expressed cardiac Troponin I (Fig. 5, right panel) . Figure 6 . Cardiac markers 15 days after in vitro culture in hMSCs and hMSCs myoc from the same batches that were used for the in vivo experiments. Nuclei are stained blue; cardiac markers as depicted in the fi gure are stained red. Abbreviations: αSA, α-sarcomeric actin; MLC2a, atrial form of myosin light chain; ANF, atrial natriuretic factor; cTnT, cardiac troponin T; cTnI; cardiac troponin I.
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hMSC hMSC myoc 136
After 15 days, of in vitro culture of cells from the same cell batches that were injected in the mice, immunohistochemistry revealed that hMSC transduced with hAd5/F50.CMV.eGFP and hAd5/F50. empty did not express αSA, Mlc2a, ANF, cTnT and cTnI (Fig. 6A-E) . Transduction of hMSCs with both hAd5/F50.CMV.myocL and hAd5/F50.CMV.eGFP, however, resulted in the expression of all these proteins (Fig. 6F-I ) with the exception of cTnI (Fig. 6J) . However, the hMSCs did not exhibit sarcomeric organization or spontaneous beating within the 15 day period of observation.
Vascular Density
Vascular density in the infarcted scar area was compared between the 3 MI groups 15 days after cell administration (Fig. 7A. ) Total blood vessel density (as determined by PECAM-1 staining) in the scar area was signifi cantly higher in the hMSC and hMSCmyoc groups (11.8 ± 2.1 %, and 11.3 ± 1.3 %; p = ns) as compared to the Medium group (5.9 ± 0.9 %; p < 0.05; Fig. 7B ). MSCs are able to diff erentiate into a number of organ specifi c cell types [4] . Therefore, the MSC population is potentially an attractive therapeutic cell type for patients with IHD with reported benefi cial eff ects on LV function in animal studies [7, 20, 6] and a initial clinical trial [21] . However, the underlying mechanism is still not fully understood as the ability of BM derived stem cells, including MSCs, to diff erentiate into cardiomyocytes has been questioned [10, 22] . This lack of cardiomyogenic diff erentiation potential prompted the development of techniques to stimulate cardiomyogenic diff erentiation [12] after in vivo transplantation. Stimulation of MSCs with 5'azacytidine [9, 3] , or a combination of several growth factors including fi broblast growth factor (FGF), insulin growth factor 1 (IGF-1) and bone morphogenetic protein-2 (BMP-2) [13] , or TGF-ß1 [14] resulted in increased cardiomyocyte diff erentiation and improved functional recovery after myocardial infarction in animal models [3, 14, 13] . However, pharmacological stimulation did either not result in cardiomyogenic diff erentiation of all treated cells [13, 14, 3] , or resulted in incomplete diff erentiation [14, 3] . To achieve eff ective cardiomyogenic diff erentiation, it is therefore mandatory to fi nd a more physiological way of improving the in vivo diff erentiation of transplanted MSCs.
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Genetic modifi cation of stem cells can be another approach to improve the cardiomyogenic diff erentiation potential of these cells. Transduction of mouse MSCs with a hypoxia-regulated heme oxygenase-1 vector improved cell survival in the ischemic mouse myocardium [23] . Also, transplantation of rat MSCs overexpressing the prosurvival gene Akt-1 in a rat MI model resulted in the prevention of remodeling and improvement of cardiac function [24] . In addition, rat MSC co-overexpressing angiopoietin, a mediator of angiogenesis, and Akt-1 restored cardiac function after permanent coronary artery occlusion [25] . However, to our knowledge, genetic modifi cation to stimulate cardiomyogenic diff erentiation of MSCs has not been employed.
We recently demonstrated that transduction of hMSCs and human myocardial scar fi broblasts with human adenovirus vectors expressing the longest splice variant of the human myocardin gene in vitro, induced the expression of a panel of genes involved in the development of cardiomyocytes as well as smooth muscle cells, but not skeletal muscle cells [18, 17] . From these results it can be concluded that transplantation of hMSC myoc and to a lesser extent of hMSC had benefi cial eff ects on infarct size and systolic and diastolic LV function 15 days after myocardial infarction as compared to the Medium only group. The decline in cardiac function in the MI+Medium group was associated with a signifi cant weight loss (qualifying as cardiac cachexia [27] ). This weight loss was signifi cantly attenuated after hMSC myoc but not after hMSC transplantation. Furthermore, in the Medium group, MI resulted in an increase in lung fl uid, indicative of pulmonary congestion, which was not observed after hMSC and hMSC myoc transplantation.
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In this study it is demonstrated that forced expression of myocardin in hMSCs confers an additional benefi cial eff ect on LV function after injection into the acutely infarcted myocardium of NOD/scid mice as compared to non myocardin transfected hMSCs. Although the improved preservation of LV function in the hMSCs myoc group could be caused by diff erentiation of hMSC myoc into a cardiomyogenic phenotype, no fully developed cardiomyocytes with sarcomeric striations were observed, making a contractile contribution of transplanted cells unlikely.
Although, hMSC myoc transplantation in the immune compromised NOD/scid mouse model of acute MI resulted in the expression of α-sarcomeric actin, ANF, atrial myosin light chain 2 (Mlc2a) and cardiac troponin T, the staining patterns for muscle-specifi c proteins remained diff use. This was consistent with the hMSC that were kept in in vitro culture, indicating that the ischemic environment did not result in a further diff erentiation towards a complete cardiomyogenic phenotype.
Furthermore, none of the myocardin transduced hMSCs expressed cTnI which is in accordance with our previous RT-PCR results in myocardin transduced hMSC, where also no cTnI but only conversely slow-twitch skeletal troponin I (ssTnI) specifi c transcripts were found [17] . ssTnI is active not only in skeletal muscle but also in the embryonic, foetal and neonatal myocardium [28] . These results therefore suggest that Myocardin expression activates an early developmental gene program, but does result into complete cardiomyocyte diff erentiation of hMSCs.
The relative preservation of LV function observed in the hMSC group and the amelioration of remodeling and contractility observed in the hMSCs myoc group can be explained by paracrine eff ects mediated by cytokines and/or other signaling molecules secreted by engrafted hMSCs and hMSC myoc . Nagaya et al. demonstrated that rat MSCs increased capillary density in a rat model of dilated cardiomyopathy by secretion of the angiogenic factors vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) [8] . Furthermore, Tang et al. demonstrated that rat MSCs engrafted in ischemic myocardium secrete angiogenic factors including stromal cell-derived factor-1α (SDF-1α), VEGF and basic fi broblast growth factor (bFGF) [5] . In line with these results we observed that hMSC and hMSC myoc injections resulted in a higher vessel density in the infarcted area as compared to medium-treated animals. As no eGFP positive cells were found incorporated into the vascular structures, this indicates that the vessels were derived from the host tissue. However, although LV function was better in the hMSC myoc treated group, vessel density in the scar area was the same in both groups. This is comparable to results from Li et al., showing that pretreatment of mouse MSCs with transforming growth factor-ß1 (TGF-ß) to enhance myogenic diff erentiation after AMI did not result in a higher microvessel density as compared to non treated MSCs [14] . Also in vitro pre-treatment of rat BMC with 5-aza did not result in an increased capillary density compared to normal BMCs in a rat model of chronic ischemia [3] .
Therefore the additional benefi cial eff ects of hMSC myoc transplantation can not be fully attributed to possible paracrine angiogenic eff ects.
Substantial engraftment of both hMSCs and hMSCs myoc after injection in the ischemic myocardium was observed. However quantitative assessment of engrafted cells revealed a signifi cant higher engraftment rate in the hMSCs myoc group. This suggests improved survival of hMSC myoc compared to hMSC, resulting in a more robust therapeutic eff ect. Which is comparable to the results from Mangi et al., who demonstrated that transduction of rat MSCs with Akt, a serinethreonine kinase and powerful survival signal, protects MSCs against apoptosis and as a result prevented remodeling and preserved LV function [24] . Additionally, this benefi cial eff ect was also dose (cell number) dependent, where a 20 fold increase in the number of transplanted cells resulted in a signifi cant increase in LV function [24] . Interestingly, Berry et al. demonstrated by atomic force microscopy that hMSC engraftment attenuates post-infarction remodeling by softening of the border zone area, thereby improving the elastic moduli resulting in a more compliant infarct scar [29] . Furthermore, our group recently demonstrated that myocardin transduction also leads to the functional expression of cellular components involved in electrical conduction [18] . Therefore transplantation of forced myocardin expressing hMSCs might result in improved electrical coupling between areas of surviving myocardium, leading to a more effi cient contraction of the scarred myocardium.
Other benefi cial eff ects of MSCs have been attributed to the secretion of substances acting on spared host cardiomyocytes to reduce apoptosis [30] , or reduce scarring [29] . In addition, MSCs also secrete insulin-like growth factor-1 (IGF-1), which plays an important role in myocardial muscle growth and can exert positive inotropic eff ects [8] . However, the exact mechanisms responsible for the observed additional benefi cial eff ects of forced myocardin expression in injected hMSCs remain at present unclear and needs to be defi ned in future studies.
L I M I T A T I O N S
Despite the clinical relevance (as most patients will be IHD patients), one of the limitations of the present study is the lack of a control group with hMSCs derived from healthy subjects, as the diff erentiation potential of IHD derived hMSCs may be less than the diff erentiation potential of healthy subjects. Secondly, we used a model of acute MI with permanent ligation of the LAD, which does not refl ect contemporary medical practice where patients with a MI undergo early reperfusion of the culprit artery. Furthermore human adenovirus serotype 5 vectors were used which do not integrate into the genome, resulting in transient expression of eGFP and myocardin genes, thereby allowing only short term experiments. Although the eff ects of forced myocardin expression were studied over a 15 day period, the stability of the observed benefi cial eff ects should be studied over a longer period.
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CONCLUSION
Forced expression of myocardin in hMSCs results in the expression of cardiomyogenic proteins but not in a true cardiomyocyte phenotype in vitro or in vivo. However compared to treatment with untreated hMSCs, injection of hMSC myoc resulted in a higher engraftment and further preservation of LV function. 
